OOIR: Observatory of International Research

Papers

(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 43. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	299
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	208
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	129
Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives	123
Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy	119
Reflections on drug resistance to KRAS inhibitors and gene silencing/editing tools for targeting mutant KRAS in cancer treatment	117
Spatiotemporal dynamics of the pre-metastatic niche: remodeling of lung microenvironment before breast cancer metastasis and targeted intervention strategies	110
VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis	109
Uveal melanoma modeling in mice and zebrafish	99
The bridging role of neutrophils in the progression of inflammation-induced colorectal cancer	93
Nutrition and dietary restrictions in cancer prevention	79
ESR1 activating mutations: From structure to clinical application	76
TSPAN1, a novel tetraspanin member highly involved in carcinogenesis and chemoresistance	68
The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications	68
Advances in epigenetic modifications and cervical cancer research	68
Targeting ferroptosis with flavonoids for cancer therapy: Mechanisms and opportunities	67
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications	66
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications	64
Mitochondrial metabolism in laryngeal cancer: therapeutic mechanisms and prospects	63
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature	61
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges	59
Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights	59
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance	57
Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer	55
Transcription factors in glioblastoma – Molecular pathogenesis and clinical implications	55

In what area of biology has a “new” type of cell death been discovered?	54
CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting	54
Targeting lipid metabolism in cancer metastasis	53
Yin yang 1: a potential regulator of immune related diseases and cancer immunity	53
Fascin-1 in primary liver cancers, perspectives for targeted therapy	52
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer	52
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells	52
Biomarkers in high grade serous ovarian cancer	51
Advances and prospects of mRNA vaccines in cancer immunotherapy	51
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights	50
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope	48
Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer	48
S100A8 and S100A9 in Cancer	47
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions	46
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy	46
Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy	45
Targeting Cdc20 for cancer therapy	45
Integrating multi-omics proteomic approaches in deciphering the tumor microenvironment and therapeutic resistance mechanisms in prostate cancer	45
Recent insights into RNA m5C methylation modification in hepatocellular carcinoma	43
The mechanics of anoikis resistance in cancer	43